Current clinical research does not reflect the diversity of patient populations, despite
continued recommendations to increase enrollment of under‐represented racial and ethnic …

Women and people from most racial and ethnic groups in the United States have historically
been under‐represented in clinical trials of investigational medical products. Inadequate …

Introduction In recent years, there has been increasing awareness of the lack of diversity
among clinical trial participants. Equitable representation is key when testing novel …

Background Considering diversity, equity, and inclusion (DEI) in clinical trials ensures that
data collected for investigational treatments reflect the populations most likely to benefit from …

Background Improving diversity in clinical trials is essential in order to produce
generalizable results. Although the importance of representation has become increasingly …

There is a growing recognition that the clinical research enterprise has a diversity problem,
given that many clinical trials recruit historically marginalized individuals or patients …

The United States witnessed a nearly 4‐fold increase in personal health care expenditures
between 1980 and 2010. Despite innovations and obvious benefits to health, participants …

Well-characterized disparities in clinical research have disproportionately affected patients
of color, particularly in underserved communities. To tackle these barriers, Genentech …

Although the population in the United States is diverse, there are disparities in healthcare
outcomes in some populations, for example, based on characteristics such as race, ethnicity …

Background• Clinical trials are needed to develop new treatments and new vaccines.•
Participants in trials should reflect the population affected by the disease, or those intended …